JP2007516173A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516173A5
JP2007516173A5 JP2006517466A JP2006517466A JP2007516173A5 JP 2007516173 A5 JP2007516173 A5 JP 2007516173A5 JP 2006517466 A JP2006517466 A JP 2006517466A JP 2006517466 A JP2006517466 A JP 2006517466A JP 2007516173 A5 JP2007516173 A5 JP 2007516173A5
Authority
JP
Japan
Prior art keywords
methyl
indazol
oxo
tetrahydro
pyrimidinecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006517466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516173A (ja
JP4869068B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/019692 external-priority patent/WO2004112719A2/en
Publication of JP2007516173A publication Critical patent/JP2007516173A/ja
Publication of JP2007516173A5 publication Critical patent/JP2007516173A5/ja
Application granted granted Critical
Publication of JP4869068B2 publication Critical patent/JP4869068B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006517466A 2003-06-19 2004-06-18 化合物 Expired - Fee Related JP4869068B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47975303P 2003-06-19 2003-06-19
US60/479,753 2003-06-19
PCT/US2004/019692 WO2004112719A2 (en) 2003-06-19 2004-06-18 Chemical compounds

Publications (3)

Publication Number Publication Date
JP2007516173A JP2007516173A (ja) 2007-06-21
JP2007516173A5 true JP2007516173A5 (enExample) 2007-08-02
JP4869068B2 JP4869068B2 (ja) 2012-02-01

Family

ID=33539215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006517466A Expired - Fee Related JP4869068B2 (ja) 2003-06-19 2004-06-18 化合物

Country Status (6)

Country Link
US (1) US7560467B2 (enExample)
EP (1) EP1633740B1 (enExample)
JP (1) JP4869068B2 (enExample)
AT (1) ATE532781T1 (enExample)
ES (1) ES2374272T3 (enExample)
WO (1) WO2004112719A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4857128B2 (ja) * 2004-02-20 2012-01-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な化合物
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
EP1756092A4 (en) * 2004-06-17 2009-12-02 Smithkline Beecham Corp NEW INHIBITORS OF RHO-KINASEN
WO2006074293A2 (en) * 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
AU2007215247B2 (en) * 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
WO2008061109A2 (en) * 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
NZ578096A (en) 2007-01-10 2011-11-25 Albany Molecular Res Inc 5-pyridinone substituted indazoles
ES2382982T3 (es) 2007-07-21 2012-06-15 Albany Molecular Research, Inc. Indazoles sustituidos con 5-piridinona y composiciones farmacéuticas de los mismos
CA2768396A1 (en) * 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Dihydropyrimidone amides as p2x7 modulators
US8536179B2 (en) 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US9279106B2 (en) 2010-11-12 2016-03-08 Georgetown University Immortalization of epithelial cells and methods of use
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2771011A4 (en) 2011-10-24 2015-04-15 Glaxosmithkline Ip No 2 Ltd CHEMICAL COMPOUNDS
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
KR20170020527A (ko) 2014-06-27 2017-02-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도
WO2016023028A2 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of Michigan G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
EP3277799B1 (en) 2015-04-03 2020-09-23 Propagenix Inc. Ex vivo proliferation of epithelial cells
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2016210403A1 (en) * 2015-06-26 2016-12-29 The Regents Of The University Of Michigan G protein-coupled receptor kinase inhibitors and methods for use of the same
EP3892718A1 (en) 2015-09-11 2021-10-13 Propagenix Inc. Ex vivo proliferation of epithelial cells
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
EP3654972A4 (en) * 2017-07-21 2021-03-17 Kadmon Corporation, LLC KINASE PROTEIN INHIBITORS CONTAINING A COIL COIL ASSOCIATED WITH RHO
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
CA3107502A1 (en) 2018-08-20 2020-02-27 Chengkang ZHANG Epithelial cell spheroids
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
WO2021024260A1 (en) * 2019-08-08 2021-02-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novel peripheral cannabinoid-1 receptor antagonists
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
US20240174637A1 (en) * 2021-01-22 2024-05-30 Grazia Piizzi Degraders of grk2 and uses thereof
JP2024538174A (ja) 2021-10-18 2024-10-18 エヴィア ライフ サイエンシズ インコーポレイテッド 肝線維症を処置するための組成物およびその使用方法
US20250235484A1 (en) 2021-10-22 2025-07-24 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314362T1 (de) * 1999-10-12 2006-01-15 Takeda Pharmaceutical Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
EP1345925B1 (en) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002066443A2 (en) * 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 2-thioxo-1,2,3,4-tetrahydropyrimidine derivatives
WO2002083648A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
EP1756092A4 (en) * 2004-06-17 2009-12-02 Smithkline Beecham Corp NEW INHIBITORS OF RHO-KINASEN

Similar Documents

Publication Publication Date Title
RU2543620C2 (ru) Производные урацила или тимина для лечения гепатита с
JP5040656B2 (ja) トリアリールカルボン酸誘導体
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
JP2006503081A5 (enExample)
US6403633B2 (en) Heteroaryl amidines, methylamidines and guanidines, and use thereof as protease inhibitors
JP2009525960A5 (enExample)
JP2003529536A (ja) C1s介在疾患および状態の処置法、およびそれのための化合物および組成物
JP2020516671A5 (enExample)
HRP20170019T1 (hr) Novi pirol-inhibitori od reduktaze s-nitrozoglutationa kao terapeutska sredstva
JP2010513304A5 (enExample)
JP2006505522A5 (enExample)
CA2466490A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2009525984A5 (enExample)
CA2454703A1 (en) Novel thiophene carboxamide derivatives
JP2016135778A (ja) シアノトリアゾール化合物の医薬用途
JP2008513500A5 (enExample)
JP2007528887A5 (enExample)
JP2016525069A (ja) シアノトリアゾール化合物
RU2009111113A (ru) Мидуляторы mglur5
RU2007107349A (ru) Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
AU765072B2 (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
CA2553423A1 (en) Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
RU2007107177A (ru) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
JP2010526106A5 (enExample)
JP2008526840A5 (enExample)